TITLE

Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting

AUTHOR(S)
L�scher, A.; de Koning, H. P.; M�ser, P.
PUB. DATE
February 2007
SOURCE
Current Pharmaceutical Design;Feb2007, Vol. 13 Issue 6, p555
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is further aggravated by the alarming incidence of treatment failures in several sleeping sickness foci, apparently indicating the occurrence of drug-resistant trypanosomes. Because of these reasons, and since vaccination does not appear to be feasible due to the trypanosomes' ever changing coat of variable surface glycoproteins (VSGs), new drugs are needed urgently. The entry of Trypanosoma brucei into the post-genomic age raises hopes for the identification of novel kinds of drug targets and in turn new treatments for sleeping sickness. The pragmatic definition of a drug target is, a protein that is essential for the parasite and does not have homologues in the host. Such proteins are identified by comparing the predicted proteomes of T. brucei and Homo sapiens, then validated by large-scale gene disruption or gene silencing experiments in trypanosomes. Once all proteins that are essential and unique to the parasite are identified, inhibitors may be found by high-throughput screening. However powerful, this functional genomics approach is going to miss a number of attractive targets. Several current, successful parasiticides attack proteins that have close homologues in the human proteome. Drugs like DFMO or pyrimethamine inhibit parasite and host enzymes alike - a therapeutic window is opened only by subtle differences in the regulation of the targets, which cannot be recognized in silico. Working against the post-genomic approach is also the fact that essential proteins tend to be more highly conserved between species than non-essential ones. Here we advocate drug targeting, i.e. uptake or activation of a drug via parasite-specific pathways, as a chemotherapeutic strategy to selectively inhibit enzymes that have equally sensitive counterparts in the host. The T. brucei purine salvage machinery offers opportunities for both metabolic and transport- based targeting: unusual nucleoside and nucleobase permeases may be exploited for selective import, salvage enzymes for selective activation of purine antimetabolites.
ACCESSION #
24325774

 

Related Articles

  • Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease. Nikolskaia, Olga V.; de A. Lima, Ana Paula C.; Kim, Yuri V.; Lonsdale-Eccles, John D.; Fukuma, Toshihide; Scharfstein, Julio; Grab, Dennis J. // Journal of Clinical Investigation;Oct2006, Vol. 116 Issue 10, p2739 

    In this study we investigated why bloodstream forms of Trypanosoma brucei gambiense cross human brain micro-vascular endothelial cells (BMECs), a human blood-brain barrier (BBB) model system, at much greater efficiency than do T. b. brucei. After noting that T. b. gambiense displayed higher...

  • A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes.  // PLoS Pathogens;Nov2010, Vol. 6 Issue 11, p1 

    No abstract available.

  • Trypanosomes, Infection and Immunity. Kaminsky, Ronald; Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p666 

    The article provides an encyclopedia entry on trypanosomes. Trypanosomes are protozoan parasites. Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are species of trypanosomes that are pathogenic to man. These species can also cause sleeping sickness. Moreover, the article also...

  • Human African trypanosomiasis in endemic populations and travellers. Blum, J.; Neumayr, A.; Hatz, C. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2012, Vol. 31 Issue 6, p905 

    Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.. Whereas most patients in endemic...

  • African Trypanosomiasis Gambiense, Italy. Bisoffi, Zeno; Beltrame, Anna; Monteiro, Geraldo; Arzese, Alessandra; Marocco, Stefania; Rorato, Giada; Anselmi, Mariella; Viale, Pierluigi // Emerging Infectious Diseases;Nov2005, Vol. 11 Issue 11, p1745 

    African trypanosomiasis caused by Trypanosoma brucei gambiense has not been reported in Italy. We report 2 cases diagnosed in the summer of 2004. Theses cases suggest an increased risk for expatriates working in trypanosomiasis- endemic countries. Travel medicine clinics should be increasingly...

  • Protein phosphatase 5 is required for Hsp90 function during proteotoxic stresses in Trypanosoma brucei. Candace Jones; Sedrick Anderson; Ujjal Singha; Minu Chaudhuri // Parasitology Research;Apr2008, Vol. 102 Issue 5, p835 

    Abstract   Trypanosoma brucei, a parasitic protozoan that causes African trypanosomiasis in human and domestic animals, adapt in various environments during their digenetic life cycle. In this study, we found that Hsp90 is crucial for the survival of this parasite. Inhibition of Hsp90...

  • Infectious disease: Genomics decodes drug action. Fairlamb, Alan H. // Nature;2/9/2012, Vol. 482 Issue 7384, p167 

    The article presents a genome-wide study that uses RNA interference in providing valuable insight on the drugs used to treat African trypanosomiasis or sleeping sickness caused by the single-celled parasite Trypanosoma brucei gambiense and T. b. rhodesiense. It mentions that among the drugs used...

  • Cerebrospinal Fluid Neopterin as Marker of the Meningo-Encephalitic Stage of Trypanosoma brucei gambiense Sleeping Sickness. Tiberti, Natalia; Hainard, Alexandre; Lejon, Veerle; Courtioux, Bertrand; Matovu, Enock; Enyaru, John Charles; Robin, Xavier; Turck, Natacha; Kristensson, Krister; Ngoyi, Dieudonné Mumba; Vatunga, Gedeão M. L.; Krishna, Sanjeev; Büscher, Philippe; Bisser, Sylvie; Ndung'u, Joseph Mathu; Sanchez, Jean-Charles // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Background: Sleeping sickness, or human African trypanosomiasis (HAT), is a protozoan disease that affects rural communities in sub-Saharan Africa. Determination of the disease stage, essential for correct treatment, represents a key issue in the management of patients. In the present study we...

  • The Human Trypanolytic Factor: A Drug Shaped Naturally. Vanhamme, Luc // Infectious Disorders - Drug Targets;Aug2010, Vol. 10 Issue 4, p266 

    African trypanosomes are responsible for sleeping sickness in man and nagana in cattle, which are both tremendous health burdens in Africa. Most African trypanosome species are killed by human serum. This is due to a serum trypanolytic particle specific of some old world monkeys and great apes,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics